Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oogenesis02:07

Oogenesis

70.8K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
70.8K
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

4.7K
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
4.7K
Ovaries01:26

Ovaries

3.0K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
3.0K
Ovarian Cycle01:27

Ovarian Cycle

4.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
4.8K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

7.3K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.3K
Cancer02:18

Cancer

55.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mes/Stem-A ovarian cancer subtypes predict sensitivity to ATR inhibition.

Oncogene·2026
Same author

Equitable authorship in Global Gynecologic Oncology trials: the Asia Pacific Gynecologic Oncology Trials Group (APGOT) framework.

Journal of gynecologic oncology·2026
Same author

Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

Journal of gynecologic oncology·2026
Same author

Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer.

Nature communications·2026
Same author

Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

British journal of cancer·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same journal

Integrating sexual health into care for patients with cancer and chronic illness.

Nature reviews. Disease primers·2026
Same journal

Chronic graft-versus-host disease.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K

Ovarian cancer.

Clare L Scott1,2,3,4,5, Susana Banerjee6, Florence Joly7

  • 1Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. scottc@wehi.edu.au.

Nature Reviews. Disease Primers
|March 5, 2026
PubMed
Summary
This summary is machine-generated.

Epithelial ovarian cancer (EOC) presents diagnostic and therapeutic challenges due to its heterogeneity. Advances in targeted therapies, like PARP inhibitors for BRCA-mutated cases, are improving outcomes, but further biomarker research is crucial.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

12.0K

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Transplantation Into the Mouse Ovarian Fat Pad
09:25

Transplantation Into the Mouse Ovarian Fat Pad

Published on: September 7, 2016

12.0K

Area of Science:

  • Gynecologic Oncology
  • Molecular Pathology
  • Cancer Therapeutics

Background:

  • Epithelial ovarian cancer (EOC) encompasses diverse diseases with varied origins, molecular features, and prognoses.
  • Low incidence of specific EOC subtypes complicates diagnosis, evidence generation, and therapeutic development.
  • Despite genetic predispositions, effective screening remains elusive, leading to frequent late-stage diagnoses.

Purpose of the Study:

  • To review the current understanding of epithelial ovarian cancer pathogenesis, diagnosis, and management.
  • To highlight challenges in EOC research and clinical care due to disease heterogeneity.
  • To discuss emerging therapeutic strategies and the need for biomarker validation.

Main Methods:

  • Review of existing literature on EOC pathogenesis, genetics, and treatment modalities.
  • Analysis of current management strategies, including surgery, chemotherapy, and targeted therapies.
  • Evaluation of the role of genetic susceptibilities and molecular characteristics in EOC.

Main Results:

  • EOCs exhibit significant heterogeneity, with varying origins and molecular profiles.
  • Standard treatment involves surgery and platinum-based chemotherapy, with targeted therapies showing promise.
  • Poly(ADP-ribose) polymerase inhibitors have improved outcomes for BRCA-mutated EOC patients.

Conclusions:

  • Effective screening for EOC is lacking, necessitating improved diagnostic and prognostic biomarkers.
  • Targeted therapies and immunotherapy show potential but require further investigation and validation.
  • Translationally focused clinical trials are essential for advancing EOC care and developing effective treatments.